Fasiglifam, also known as TAK-875, is a G protein-coupled receptor 40 (GPR40) agonist previously investigated as a potential treatment for type 2 diabetes due to its role in enhancing glucose-dependent… Read more





Fasiglifam, also known as TAK-875, is a G protein-coupled receptor 40 (GPR40) agonist previously investigated as a potential treatment for type 2 diabetes due to its role in enhancing glucose-dependent insulin secretion. This category provides essential analytical tools for pharmaceutical laboratories, including the active pharmaceutical ingredient, its racemic and enantiomeric forms, and synthetic intermediates such as the biphenyl-methanol precursor. Furthermore, stable isotope labelled compounds like Fasiglifam-13C-d3 serve as critical internal standards for precise quantification during method validation and pharmacokinetic analysis. By offering these high-quality reference standards, the collection supports rigorous impurity profiling and quality control workflows, enabling researchers to accurately identify and monitor degradation products and process-related impurities throughout the drug development lifecycle.